Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of telotristat etiprate in carcinoid syndrome
NL-OMON44470Phase 3Active, not recruiting
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of telotristat ethyl in Carcinoid Syndrome (CS) (2 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Long-term safety and tolerability of telotristat etiprate. Started May 2015; status: active, not recruiting.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NL-OMON44470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44470.